Carbenoxolone

Identification

Name
Carbenoxolone
Accession Number
DB02329
Description

An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

Type
Small Molecule
Groups
Experimental
Structure
Thumb
Weight
Average: 570.7566
Monoisotopic: 570.355653954
Chemical Formula
C34H50O7
Synonyms
  • Carbenoxolona
  • Carbenoxolone

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U3-alpha-(or 20-beta)-hydroxysteroid dehydrogenaseNot AvailableStreptomyces exfoliatus
UCorticosteroid 11-beta-dehydrogenase isozyme 1
inhibitor
Humans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Carbenoxolone disodiumF1MP7242Z57421-40-1BQENDLAVTKRQMS-SBBGFIFASA-L
International/Other Brands
Carbelone (Royal) / Carbosan (Rowa) / Carboxe (Shiteh Organic) / Copu (Winston) / Herpesan (Rowa) / Rösch & Handel (Rowa) / Rowadermat (Rösch & Handel) / Rowagel (Rowa) / Sanodin (Ern)

Categories

ATC Codes
A02BX01 — CarbenoxoloneA02BX71 — Carbenoxolone, combinations with psycholepticsA02BX51 — Carbenoxolone, combinations excl. psycholeptics
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing six isoprene units.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Triterpenoids
Direct Parent
Triterpenoids
Alternative Parents
Tricarboxylic acids and derivatives / Fatty acid esters / Cyclohexenones / Carboxylic acid esters / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
Aliphatic homopolycyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Carboxylic acid ester / Cyclohexenone / Fatty acid ester / Fatty acyl / Hydrocarbon derivative / Ketone
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
MM6384NG73
CAS number
5697-56-3
InChI Key
OBZHEBDUNPOCJG-WBXJDKIVSA-N
InChI
InChI=1S/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1
IUPAC Name
(2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-[(3-carboxypropanoyl)oxy]-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
SMILES
[H][C@@]1(CC[C@@]2(C)[C@@]([H])(CC[C@]3(C)[C@]2([H])C(=O)C=C2[C@]4([H])C[C@](C)(CC[C@]4(C)CC[C@@]32C)C(O)=O)C1(C)C)OC(=O)CCC(O)=O

References

Synthesis Reference

Gottfried, S. and Baxendale, L.; U.S. Patent 3,070,623; December 25,1962; assigned to Biorex Laboratories Limited, England.

General References
  1. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR: 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6734-9. Epub 2004 Apr 7. [PubMed:15071189]
PubChem Compound
636403
PubChem Substance
46508820
ChemSpider
552190
BindingDB
50247012
RxNav
2017
ChEMBL
CHEMBL499915
ZINC
ZINC000003977823
Therapeutic Targets Database
DNC000388
PDBe Ligand
CBO
Wikipedia
Carbenoxolone
PDB Entries
1hdc / 2bel / 6wbi / 6wbl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Gel
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)292.5 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.000738 mg/mLALOGPS
logP5.46ALOGPS
logP6.3ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)4.04ChemAxon
pKa (Strongest Basic)-5.1ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area117.97 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity154.31 m3·mol-1ChemAxon
Polarizability64.99 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9612
Blood Brain Barrier+0.809
Caco-2 permeable-0.5933
P-glycoprotein substrateSubstrate0.83
P-glycoprotein inhibitor INon-inhibitor0.7249
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterNon-inhibitor0.8358
CYP450 2C9 substrateNon-substrate0.8343
CYP450 2D6 substrateNon-substrate0.9271
CYP450 3A4 substrateSubstrate0.7984
CYP450 1A2 substrateNon-inhibitor0.9145
CYP450 2C9 inhibitorNon-inhibitor0.8921
CYP450 2D6 inhibitorNon-inhibitor0.9482
CYP450 2C19 inhibitorNon-inhibitor0.9274
CYP450 3A4 inhibitorNon-inhibitor0.6959
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8713
Ames testNon AMES toxic0.821
CarcinogenicityNon-carcinogens0.9485
BiodegradationNot ready biodegradable0.9745
Rat acute toxicity2.3981 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9285
hERG inhibition (predictor II)Non-inhibitor0.7892
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Streptomyces exfoliatus
Pharmacological action
Unknown
General Function
Androstan-3-alpha,17-beta-diol dehydrogenase activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
P19992
Uniprot Name
3-alpha-(or 20-beta)-hydroxysteroid dehydrogenase
Molecular Weight
26483.77 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
11-beta-hydroxysteroid dehydrogenase [nad(p)] activity
Specific Function
Catalyzes reversibly the conversion of cortisol to the inactive metabolite cortisone. Catalyzes reversibly the conversion of 7-ketocholesterol to 7-beta-hydroxycholesterol. In intact cells, the rea...
Gene Name
HSD11B1
Uniprot ID
P28845
Uniprot Name
Corticosteroid 11-beta-dehydrogenase isozyme 1
Molecular Weight
32400.665 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 13:24 / Updated on February 21, 2021 18:51